Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." ...

Mesoblast says FDA feedback supports filing plans for its cell therapy to treat chronic back pain, showing reduced pain and ...

Meso Scale Diagnostics, LLC is a biotechnology company that develops, manufactures, and markets instruments and assays for the life sciences industry. The company was founded in 1995 by Christopher P.

A downtrend has been apparent in Mesoblast Limited (MESO) lately. While the stock has lost 10.8% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last ...

Mesoblast (MESO) stock jumps as the company's lead asset Ryoncil adds $35.1M in revenue during the December quarter, marking 60% QoQ growth. Read more here.

) has been revised to $20.25 / share. This is an increase of 11.48% from the prior estimate of $18.16 dated December 5, 2025. The price target is an average of many targets provided by analysts. The ...

Mesoblast Limited’s MESO shares surged 78.6% on Mar 26, after an encouraging regulatory update from the FDA for its lead product candidate, remestemcel-L, which is being developed for the treatment of ...

MESO has a diversified portfolio targeting inflammatory conditions, majorly led by products Remestemcel-L and Rexlemestrocel-L. The recent FDA rejection of Remestemcel-L poses a challenge, but ...